安科生物公告，公司高级管理人员姚建平已于2025年11月13日至11月14日通过集中竞价方式，以10.94 元/股均价减持100万股，占公司总股本0.06%，减持计划实施完毕。减持前持股676.22万股，占0.40%， 减持后持股576.22万股，占0.34%，其中无限售条件股份由178.9万股降至78.9万股，有限售条件股份 497.33万股保持不变。此前减持计划于2025年9月4日披露，拟减持上限同为100万股。 ...

南财智讯11月17日电，安科生物公告，公司高级管理人员姚建平先生在减持计划期间通过集中竞价交易 方式合计减持公司股份100万股，占公司总股本的0.06%，本次减持计划已实施完毕。减持后，姚建平 持有公司股份5,762,235股，占公司总股本的0.34%。本次减持行为符合相关法律法规规定，与此前披露 的减持计划一致，不会导致公司控制权变更，不影响公司治理结构和持续经营。 ...

安徽安科生物工程（集团）股份有限公司 关于高级管理人员减持计划实施完成的公告 公司高级管理人员姚建平先生保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于2025年9 月4日披露了《关于部分高级管理人员减持计划的预披露公告》（公告编号： 2025-049），公司高级管理人员姚建平先生计划自本公告披露之日起15个交易日 后的3个月内通过集中竞价交易或大宗交易方式减持公司股份100万股（占公司总 股本比例的0.06%）。若在减持计划实施期间公司发生送红股、转增股本、增发新 股或配股等股本变动事项的，本次拟减持股份数量将进行相应调整。 近日，公司收到姚建平先生出具的《关于股份减持计划实施完成告知函》， 姚建平先生于减持计划期间合计减持公司股份100万股，占公司总股本比例的 0.06%，本次减持计划实施完毕。具体情况如下： 一、股东减持基本情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司总 股本比例 | 股份来源 | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.963 billion yuan for the first three quarters of 2025, a year-on-year increase of 2.15%, and a net profit attributable to the parent company of 551 million yuan, a year-on-year decrease of 6.48%. In Q3 2025 alone, the revenue was 670 million yuan, a year-on-year increase of 7.7%, and the net profit was 185 million yuan, a year-on-year increase of 6.56% [4][5] - The company's main business has stabilized and is showing signs of recovery, with positive growth in both revenue and profit in Q3, primarily driven by the growth in revenue from growth hormones and antibody drugs. The decline in profit for the first three quarters is attributed to increased R&D investment, which reached 145 million yuan, a year-on-year increase of 13.08% [5] - The company has successfully introduced two significant long-acting products through business development (BD) collaborations, enhancing its market position in the fields of pediatric growth and assisted reproduction [6] - The company’s affiliate, Bosheng Jian, has made significant progress in its cell therapy platform, with the CD7 CAR-T (PA3-17 injection) being included as a breakthrough therapy and approved for key Phase II clinical trials [7] Financial Summary - The company expects revenues for 2025, 2026, and 2027 to be 2.677 billion yuan, 3.050 billion yuan, and 3.529 billion yuan, respectively, with year-on-year growth rates of 5.6%, 13.9%, and 15.7%. The net profit attributable to the parent company is projected to be 756 million yuan, 848 million yuan, and 987 million yuan for the same years, with year-on-year growth rates of 6.9%, 12.1%, and 16.4% [8][9] - Key financial metrics for 2025 include a gross margin of 78.4%, a return on equity (ROE) of 17.4%, and earnings per share (EPS) of 0.45 yuan [11]

11月17日，安科生物盘中下跌2.03%，截至10:04，报10.61元/股，成交1.13亿元，换手率0.86%，总市值 177.45亿元。 安科生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：民营医院、基因测 序、互联医疗、医疗美容、肝炎治疗等。 截至10月31日，安科生物股东户数7.69万，较上期增加4.63%；人均流通股15886股，较上期减少 4.43%。2025年1月-9月，安科生物实现营业收入19.63亿元，同比增长2.15%；归母净利润5.51亿元，同 比减少6.48%。 分红方面，安科生物A股上市后累计派现26.62亿元。近三年，累计派现12.52亿元。 机构持仓方面，截止2025年9月30日，安科生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1952.26万股，相比上期减少126.90万股。招商国证生物医药指数A（161726）位居第五大 流通股东，持股1596.17万股，相比上期减少273.29万股。创新药（159992）位居第七大流通股东，持股 1121.77万股，相比上期增加19.13万股。南方中证1000ETF（512100）位居第九大流通 ...

Core Viewpoint - On November 17, a total of 17 listed companies will have their restricted shares unlocked, with a total market value of approximately 22.745 billion yuan [1] Summary by Category Restricted Shares Unlocking - The total number of restricted shares unlocking on this date is significant, with a total market value of about 22.745 billion yuan [1] - Specific companies and their respective unlocking details include: - Yingte Group (000411): 273,600 shares from equity incentive [1] - East China Pharmaceutical (000963): 1,630,300 shares from equity incentive [1] - Innovation New Materials (600361): 2.867 billion shares from other types [1] - Fida Environmental Protection (600526): 152 million shares with extended lock-up period [1] - New Mileage (002219): 8.7 million shares from equity incentive [1] - Anke Bio (300009): 12.3941 million shares from equity incentive [1] - Songcheng Performance (300144): 2.16 million shares from equity incentive [1] - Keheng Co., Ltd. (300340): 511,400 shares from equity incentive [1] - Haoxiangni (002582): 1 million shares from equity incentive [1] - Zhongzhi Technology (301361): 2.252 million shares from pre-issue [1] - Jack Co., Ltd. (603337): 2.4576 million shares from equity incentive [1] - Tian'ao Electronics (002935): 105,400 shares from equity incentive [1] - Huatuo Cable (605196): 556,000 shares from equity incentive [1] - Yongshuntai (001338): 266 million shares from pre-issue [1] - New World (301277): 149 million shares from pre-issue [1] - Yongxi Electronics (688362): 130 million shares [1] - Kangxi Communication (688653): 3.184 million shares [1]

Core Insights - Anke Bio announced a strategic partnership with Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. to promote the sales of the PA3-17 injection product, which is a CAR-T cell therapy targeting CD7 [1] - The PA3-17 injection is the first globally approved CAR-T cell therapy for clinical trials targeting CD7, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies [1] - The product has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) and is currently in a critical Phase II clinical trial [1] Summary by Sections - **Strategic Partnership**: Anke Bio and Boshengji have signed a framework agreement for exclusive agency rights for the PA3-17 injection in Greater China, with a formal agreement to follow after the product's market application submission [1] - **Product Details**: PA3-17 injection is developed by Boshengji's subsidiary and is the first of its kind to receive clinical trial approval, focusing on a significant medical need in hematologic cancers [1] - **Future Collaboration**: Boshengji has committed to prioritizing Anke Bio as the exclusive agency for future product launches, ensuring a long-term collaboration for sales and promotion in the region [1]

Core Viewpoint - Anke Bio (300009) is advancing its participation in the CAR-T therapy development through its affiliate, Boshengji, which has initiated a dose escalation plan for its LV009 product and is currently enrolling patients for clinical trials [1] Group 1 - Anke Bio's affiliate, Boshengji, has completed the design for the accelerated dose escalation scheme for its In vivo CAR-T LV009 [1] - The first patient has been enrolled in the clinical trial, with efficacy evaluation expected to begin in approximately two weeks [1] - Boshengji is simultaneously screening additional patients and has initiated ethical reviews at three hospitals to support IND application and business development data acquisition [1]

Core Viewpoint - Anke Bio (300009) announced that its affiliate, Boshengji, has included the PA3-17 injection in the breakthrough therapy category and has entered the critical Phase II clinical trials, aiming to complete patient enrollment within one year and submit a pre-NDA communication request by Q1 2027 [1] Group 1: Clinical Development - The PA3-17 injection has been classified as a breakthrough therapy and is currently in Phase II clinical trials [1] - The company aims to complete the enrollment of all patients within one year [1] - A pre-NDA communication request is expected to be submitted by Q1 2027 [1] Group 2: Indication Expansion - The company is currently submitting an application for pediatric indications [1] - Following the approval for T-ALL/LBL indications, Boshengji plans to expand into other indications, including peripheral T-cell lymphoma, NKT lymphoma, and acute myeloid leukemia [1]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]